CasLoc logo
All Cases PTAB Litigations UPC Oppositions

ProStrakan, Inc. v. Actavis Laboratories UT, Inc.

2:16-cv-00044

Overview

Case Number 2:16-cv-00044
Filing Date 2016-01-13
Status Terminated
Termination Date 2018-09-28
Court District Court, E.D. Texas (txed)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Both

Parties

Mediator

David Folsom NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Defendant

Actavis Laboratories UT, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Allergan plc Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

ProStrakan, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Counter Defendant

Strakan International S.a r.l. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, E.D. Texas (txed)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7608282
Transdermal granisetron
Filed: 2004-02-05
Issued: 2009-10-27
Expired (Term Ended) +352d PTA
Expires: 2025-01-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+352 days) / Cellect Scrutiny β€” Over 352 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

10

Dispositive

2

Granted

3

Denied

0

Pending / Review

7

Motions by Category

Claim Construction / Markman Filing 7 Motion to Dismiss 2 Procedural / Extension Motion 1

Key Dispositive Motions & Rulings

Motion to Dismiss Granted
ORDER granting 38 Joint MOTION to Dismiss Defendant Allergan PC Without Prejudice filed by Actavis Laboratories UT, Inc.., Allergan plc and Allergan plc termina...
Entry #39 • 2016-11-21 Document →
Motion to Dismiss Granted
Joint MOTION to Dismiss Defendant Allergan PC Without Prejudice by Actavis Laboratories UT, Inc.. (Attachments: # 1 Text of Proposed Order Proposed Order Dismis...
Entry #38 • 2016-11-17 Document →
Claim Construction / Markman Filing Pending / Under Review
Markman Hearing
Entry #60 • 2017-06-22 Document →
Claim Construction / Markman Filing Pending / Under Review
Claim Construction Chart/Prehearing Statement
Entry #59 • 2017-06-01 Document →
Claim Construction / Markman Filing Pending / Under Review
Reply to Claim Construction Brief
Entry #57 • 2017-05-25 Document →
Claim Construction / Markman Filing Pending / Under Review
Reply to Claim Construction Brief
Entry #53 • 2017-05-18 Document →

Docket Entries

(63 total)
Pleading / Complaint

COMPLAINT for Patent Infringement against Actavis Laboratories UT, Inc., Allergan plc ( Filing fee $ 400 receipt number 0540-5564347.), filed by ProStrakan, Inc., Strakan International S.a r.l.. (Attachments: # 1 Exhibit A - U.S. Patent No. 7,608,282, # 2 Civil Cover Sheet)(Davis, William) (Entered: 01/13/2016)

Entry #1 • 2016-01-13
1
Pleading / Complaint

COMPLAINT for Patent Infringement against Actavis Laboratories UT, Inc., Allergan plc ( Filing fee $ 400 receipt number 0540-5564347.), filed by ProStrakan, Inc., Strakan International S.a r.l.. (Attachments: # 1 Exhibit A - U.S. Patent No. 7,608,282, # 2 Civil Cover Sheet)(Davis, William) (Entered: 01/13/2016)

Entry #1 • 2016-01-13
2
Pleading / Complaint

COMPLAINT for Patent Infringement against Actavis Laboratories UT, Inc., Allergan plc ( Filing fee $ 400 receipt number 0540-5564347.), filed by ProStrakan, Inc., Strakan International S.a r.l.. (Attachments: # 1 Exhibit A - U.S. Patent No. 7,608,282, # 2 Civil Cover Sheet)(Davis, William) (Entered: 01/13/2016)

Entry #1 • 2016-01-13
2

NOTICE of Attorney Appearance by Kerry B McTigue on behalf of All Plaintiffs (McTigue, Kerry) (Entered: 01/14/2016)

Entry #2 • 2016-01-14
1

NOTICE of Attorney Appearance by Barry P Golob on behalf of All Plaintiffs (Golob, Barry) (Entered: 01/14/2016)

Entry #3 • 2016-01-14
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc